Release Date: March 31, 2025
Expiration Date: March 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in limited-stage small cell lung cancer (LS-SCLC). In this educational program, these experts discuss the latest developments reshaping the treatment landscape for LS-SCLC. Among the topics of discussion are practical considerations and impact of immunotherapy and combination approaches in LS-SCLC, challenges in SCLC treatment, and future research and clinical interventions aimed to meet the needs of patients in real-world settings
This educational activity is an archive of the live symposium held on February 20, 2025.
Target Audience
This educational activity is directed toward medical oncologists, radiation oncologists, pathologists, molecular pathologists, thoracic surgeons, and pharmacists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate current standards of care for LS-SCLC, including the role of concurrent CRT and the integration of evidence-based therapeutic strategies.
- Interpret emerging clinical trial data to assess the potential impact of immunotherapy and combination approaches in LS-SCLC management.
- Discuss the practical application of immunotherapy in LS-SCLC, including patient selection, timing, duration, and strategies to monitor and manage treatment-related toxicities.
Lauren Averett Byers, MD
Professor and Thoracic Section Chief
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Amgen, AstraZeneca, Jazz Pharmaceuticals; Consultant/Adviser: AbbVie, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, BeiGene, Chugai Pharmaceuticals, Genentech, Jazz Pharmaceuticals, Merck, Puma.
Percy Lee, MD, FASTRO
Professor and Vice Chair of Clinical Research
Department of Radiation Oncology
Medical Director of Orange County and Coastal Regions
Lennar Foundation Cancer Center
City of Hope National Medical Center
Irvine, CA
Disclosures: Grant/Research Support: AstraZeneca, GE HealthCare, Varian; Consultant: AstraZeneca, Genentech, Johnson & Johnson, Roche, RTOG Foundation; Honoraria Recipient: AstraZeneca.
Erminia Massarelli, MD, PhD, MS
Division Chief, Hematology/Oncology
University of Texas Tyler School of Medicine
Tyler, TX
Disclosures: Consultant: AbbVie; Adviser: AstraZeneca, Bristol Myers Squibb, Gilead, Janssen, Mirati Therapeutics, Sanofi.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians’ Education Resource®, LLC (PER®) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. PER has approved this application-based activity for 1.00 ACPE CE hours. The Universal Activity Number for this activity is 0661-0000-25-003-H01-P. Eligibility for credits requires full attendance, and submission of activity evaluation, NABP e-pid# and month/date of birth within 45 days of activity completion. Please allow up to 60 days for credit processing. No partial credits are given. This UAN expires June 30, 2026.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
